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Summary
Neuroactive metabolites of the kynurenine pathway (KP) of
tryptophan degradation have been implicated in the patho-
physiology of neurodegenerative disorders, including Hun-
tington’s disease (HD) [1]. A central hallmark of HD is neuro-
degeneration caused by a polyglutamine expansion in the
huntingtin (htt) protein [2]. Here we exploit a transgenic
Drosophila melanogaster model of HD to interrogate the
therapeutic potential of KP manipulation. We observe that
genetic and pharmacological inhibition of kynurenine
3-monooxygenase (KMO) increases levels of the neuropro-
tective metabolite kynurenic acid (KYNA) relative to the
neurotoxic metabolite 3-hydroxykynurenine (3-HK) and
ameliorates neurodegeneration. We also find that genetic
inhibition of tryptophan 2,3-dioxygenase (TDO), the first
and rate-limiting step in thepathway, leads to a similar neuro-
protective shift toward KYNA synthesis. Importantly, we
demonstrate that the feeding of KYNA and 3-HK to HDmodel
flies directly modulates neurodegeneration, underscoring
the causative nature of these metabolites. This study
provides the first genetic evidence that inhibition of KMO
and TDO activity protects against neurodegenerative dis-
ease in an animal model, indicating that strategies tar-
geted at two key points within the KP may have therapeutic
relevance in HD, and possibly other neurodegenerative
disorders.
Results
The kynurenine pathway (KP), responsible for >95% of the
degradation of tryptophan in mammals, contains three metab-
olites shown to be neuroactive: kynurenic acid (KYNA),
3-hydroxykynurenine (3-HK), and quinolinic acid (QUIN) (Fig-
ure 1A) [1]. 3-HK and QUIN are neurotoxic by distinct mech-
anisms—3-HK is a potent free-radical generator [1, 3, 4],
whereas QUIN is an excitotoxic N-methyl-D-aspartate (NMDA)
receptor agonist [5, 6]. KYNA, on the other hand, has neuro-
protective properties as an antagonist of excitatory amino
acid receptors and a free-radical scavenger [7–10]. Fruit flies
do not synthesize QUIN [11], providing a unique genetic model*Correspondence: fg36@le.ac.ukto study the roles of 3-HK and KYNA in neurodegeneration
(Figure 1A). Levels of these metabolites can be modulated
by agents that inhibit the first step in the KP (catalyzed in
mammals by tryptophan 2,3-dioxygenase [TDO], indoleamine
2,3-dioxygenase [IDO], and indoleamine 2,3-dioxygenase 2) or
by inhibiting kynurenine 3-monooxygenase (KMO), which lies
at the branching point between 3-HK and KYNA synthesis.
Both IDO and KMO inhibitors have shown promise in preclin-
ical studies of a variety of human disorders [12]. In flies, KMO
and TDO are encoded by the genes cinnabar (cn) and
vermillion (v), respectively, which are expressed in the eye
and have been extensively characterized for their role in eye
color pigmentation [13]. The role of the KP in eye function is
conserved from flies to humans, where the pathway plays
a central role in the formation of ultraviolet irradiation (UV)
filters in the lens [14]. Notably, fly mutants that perturb the
KP have been found to alter brain plasticity and modulate
life span [15, 16]. To date, the therapeutic potential of KMO
specifically, and the KP in general, has not been explored in
an animal model of neurodegeneration, and the role of KP
metabolites in this disease process has not been clarified.
This study interrogates these questions using both genetic
and pharmacological tools in a fruit fly model of Huntington’s
disease (HD).
HD Model Flies Exhibit Perturbed Flux through the KP
Increased flux through the central KP is correlated to
pathology in HD patients, as well as in mouse and yeast
models of HD [1]. To examine whether the pathway is dysfunc-
tional in a similar fashion in HD model flies, we analyzed 3-HK
and KYNA in fly heads and determined the 3-HK/KYNA ratio,
an established measure of flux through the central KP [17].
We employed the bipartite GAL4/UAS system with the elav-
GAL4 driver to direct panneuronal expression of either
a mutant huntingtin (htt) exon 1 fragment (Htt93Q) or a nonex-
panded htt exon 1 fragment (Htt20Q) [18]. Expression of
Htt93Q in flies provides a well-characterized model of HD
and presents several disease-relevant phenotypes, including
degeneration of photoreceptor neurons (rhabdomeres)—a
robust readout for neurodegeneration. We found an w2- to
3-fold increase in the 3-HK/KYNA ratio in HD flies as
compared to controls at day 1 and day 7 posteclosion (Fig-
ure 1B; see also Table S1 available online), supporting a path-
ogenic role for the KP in this model. A similar effect was also
observed in flies expressing Htt20Q (Figure S1). We then
analyzed 3-HK and KYNA levels in putative null mutant flies
lacking either KMO (cn3/cn3) or TDO (v36f/v36f). Synthesis
of 3-HK was essentially eliminated in KMO-deficient flies,
whereas KYNA levels increased 3.3- to 5.8-fold versus con-
trols, leading to a dramatic decrease in the 3-HK/KYNA ratio
(Figure 1C). Similarly, in TDO-deficient flies, 3-HK was much
reduced (w97%), and the remaining KP metabolism was
shifted toward KYNA synthesis, resulting in a significant
w70%–95% reduction in the 3-HK/KYNA ratio (Figure 1D).
The presence of KP metabolites suggests that the v36f
mutation may not be a complete amorph, but a strong hypo-
morph, and that some TDO activity remains in these flies,
albeit at much-reduced levels.
Figure 1. Schematic Representation of the
Kynurenine Pathway in Drosophila melanogaster
(A) Kynurenine pathwaymetabolites are essential
for formation of the ommochromes, biological
pigments required for wild-type eye color in the
fly. Unlike yeast and mammalian counterparts,
the neurotoxic metabolite quinolinic acid (QUIN)
is not present in Drosophila, making the fly
a unique system to model the effects of
3-hydroxykynurenine (3-HK) and kynurenic acid
(KYNA) on neurodegeneration.
(B) Flies expressing Htt93Q exhibit increased
3-HK/KYNA ratios at day 1 and day 7 relative to
UAS controls.
(C and D) cn3/cn3 (C) and v36f/v36f (D) flies show
a significant decrease in 3-HK/KYNA at day 1
versus +/+ genotypes.
(E) elav-Gal4 RNAi knockdown of cn and v KK
lines leads to a decrease in 3-HK/KYNA at day 1
versus +/+ genotypes. RNAi knockdown of cn
and v was confirmed by qPCR analysis (Fig-
ure S2). Statistical comparisons by analysis of
variance (ANOVA) with Newman-Keuls post hoc
tests. n = 4–8 samples per genotype. (*p < 0.05;
**p < 0.01; ***p < 0.001; ns = not significant).
Data are shown as means 6 standard errors of
the mean (SEMs).
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The results above highlight the value of KMO- and TDO-
deficient flies for testing the role of 3-HK and KYNA in mutant
htt toxicity in vivo. We therefore generated elav-GAL4>UAS-
Htt93Q (Htt93Q-expressing) flies carrying cn3, v36f, or their
respective UAS-RNA interference (RNAi) transgenes and as-
sayed neurodegeneration as well as 3-HK/KYNA ratios. In
both cn and v mutants expressing Htt93Q, as well as in the
RNAi lines, metabolites were robustly shifted toward KYNA
synthesis (Figures 1C–1E), an environment predicted to be
more neuroprotective. As expected, control flies exhibited
seven visible rhabdomeres, whereas robust degeneration of
these neuronswas observed inHtt93Qflies.We then examinedrhabdomere loss in the eyes of cn3/cn3
and v36f/v36f flies expressing Htt93Q
compared to controls and observed
a significant w26% rescue of neurons
in cn3/cn3 flies and an w43% rescue in
v36f/v36f adults at day 1, aswell as neuro-
protection, albeit reduced, at day 7
(w15% and w29%, respectively)
(Figures 2A–2C). Furthermore, we found
that panneuronal RNAi knockdown of cn
and v conferred similar or better levels of
rescue of rhabdomeres at both day 1
(w65% and w67%, respectively) and
day 7 (w55% and w54%) (Figures 2D
and 2E). Htt93Q-expressing flies hetero-
zygous for cn3 (cn3/+) neither exhibited
significantly increased rhabdomere
numbers (Figure 2B) nor showed any
difference in 3-HK/KYNA ratio com-
pared to Htt93Q flies (Figure 1C). Con-
versely, Htt93Q v36f/+ flies exhibited
both partial rescue of neurodegenera-
tion (Figures 2Band2C) anda significantdecrease in 3-HK/KYNA ratio (Figure 1D). Taken together,
these genetic data reveal an association between increased
3-HK/KYNA ratios in Htt93Q flies and neurodegeneration.
KMO Inhibitors Ameliorate Neurodegeneration
in HD Model Flies
Having shown that genetic disruption at two key steps in the
KP ameliorates an HD-relevant phenotype, we tested the effi-
cacy of a well-characterized KMO inhibitor, UPF 648 [19], as
a potential therapeutic modulator of the KP. We selected
newly eclosed adult flies and placed themonmedia containing
one of three different doses of UPF 648 (30 mM, 100 mM,
300 mM) or vehicle (phosphate-buffered saline [PBS]). Flies
were transferred to new media every day, and rhabdomeres
Figure 2. Inhibition of cn and v Ameliorates
Neurodegeneration in the Fly
(A) Pseudopupil images from wild-type flies, HD
flies, and HD flies carrying either cn3 or v36f amor-
phic alleles at day 1. In wild-type and in cn and v
flies not expressing Htt93Q, seven rhabdomeres
are visible per ommatidium.
(B and D) Quantification of mean rhabdomeres
(6 SEM) per ommatidium in Htt93Q, Htt93Q
cn3/cn3, Htt93Q cn3/+, Htt93Q v36f/v36f, Htt93Q
v36f/+, Htt93Q cn RNAi, and Htt93Q v RNAi flies
at day 1 and day 7 after eclosion. Statistical
comparisonsbyANOVAandpost hoc tests versus
Htt93Qflies.n=11–29fliespergenotype (*p<0.05;
**p < 0.01; ***p < 0.001). ns = not significant.
(C and E) Percent rescue of neurodegeneration in
Htt93Q cn3/cn3, Htt93Q cn3/+, Htt93Q v36f/v36f,
Htt93Q v36f/+, Htt93Q cn RNAi, and Htt93Q v
RNAi flies at day 1 and day 7.
(F) Rhabdomere neurodegeneration at day 7 is
ameliorated by treatment with the KMO inhibitor
UPF 648 (doses in mM) relative to PBS control.
n = 10–13 flies per treatment (***p < 0.001,
ANOVA and post hoc tests).
(G) Treatment with 100 mM UPF 648 shifts
KP pathway flux toward synthesis of KYNA
(**p < 0.01, Student’s t test). Flies were tested at
day 7. n = 5 samples per treatment.
Data are shown as means 6 standard errors of
the mean (SEMs).
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tion (up tow90% rescue of neurodegeneration, Figure 2F) and
a significant shift toward KYNA synthesis (Figure 2G). To
further support the view that neuroprotection is due to inhibi-
tion of KMO, we tested two additional KMO inhibitors: JM6,
a novel KMO inhibitor that is protective in mouse models of
HD and Alzheimer’s disease [20], and Ro 61-8048 [21],
a compoundwe previously found protective in HDmodel yeast
[1]. We observed similar neuroprotective results for these
inhibitors (Figures S3A and S3B). To test whether off-target
effects were contributing to the observed neuroprotection,
we treated Htt93Q cn flies with 30 mM Ro 61-8048. Strikingly,we found that Ro 61-8048 conferred
no added protection to Htt93Q cn flies
(FigureS3C).Thus, eithergeneticorphar-
macological inhibition of KMO resulted in
asimilar level ofneuroprotection—clearly
showing that these beneficial effects are
due to specific inhibition of KMO and
not to off-target effects of Ro 61-8048.
These studies reveal that pharmacolog-
ical as well as genetic inhibition of KMO
is protective in Htt93Q-expressing flies.
3-HK and KYNA Modulate
Neurodegeneration
In order to directly test the causative
role of 3-HK in Htt93Q toxicity, we then
fed 3-HK to Htt93Q and Htt93Q cn3/cn3
flies. To ensure that flies were being
fed the metabolite at physiological
levels, we took advantage of previous
work describing restoration of wild-
type eye pigmentation in cn3 flies fed
3-HK as larvae [22]. Flies were matedso that eggs of the desired genotype were deposited directly
onto media containing 3-HK, and thus emerging larvae were
fed themetabolite throughout development.We tested a series
of doses and found that 0.8 mg/ml was the minimum sufficient
to restore wild-type eye color to newly emerged cn3 flies (Fig-
ure 3A). We therefore fed this dose of 3-HK, as well as a higher
one of 1.4 mg/ml, to Htt93Q and Htt93Q cn3/cn3 larvae and
scored rhabdomeres in newly eclosed adult flies. 3-HK feeding
led to a dose-dependent restoration of neurodegeneration in
Htt93Q cn3/cn3 flies (Figure 3B). Notably, at the highest dose
of 3-HK, no significant rhabdomere rescue in Htt93Q cn3/cn3
flies was observed compared to Htt93Q (p = 0.15), suggesting
Figure 3. 3-HK and KYNA Directly Modulate
Neurodegeneration in Htt93Q Flies
(A) Representative images of newly emerged (day
0) cn3 flies fed 3-HK, showing restoration of wild-
type (WT) eye color. Doses of 0.4, 0.6, 0.8, 1.1, or
1.4 mg/ml 3-HK were fed to cn3 and control flies
(0.6 and 1.1 mg/ml not shown).
(B) 3-HK abrogates cn3 protection in day
0 Htt93Q flies (ns = not significant, p = 0.15). n =
8–12 flies per treatment. Comparisons were
made between genotypes with the same treat-
ment.
(C) 3-HK feeding leads to significantly increased
3-HK/KYNA ratios in newly emerged Htt93Q and
Htt93Q cn3 flies versus untreated controls. n =
3–6 samples per treatment.
(D) KYNA feeding at 1 mg/ml (**p < 0.01) and
5 mg/ml (*p < 0.05) increases rhabdomere
number at day 0. n = 12 flies per treatment. Statis-
tical comparisons by ANOVA and post hoc tests
for (B), (C), and (D) (*p < 0.05; **p < 0.01;
***p < 0.001).
(E) Feeding of 5 mg/ml KYNA decreases the
3-HK/KYNA ratio in Htt93Q flies at day 0 (*p =
0.05, Student’s t test). n = 4–5 samples per
condition.
Data are shown as means 6 standard errors of
the mean (SEMs).
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inhibition. Even at the highest dose, 3-HK levels in Htt93Q
cn3/cn3 flies did not exceed levels in untreated control
Htt93Q flies (Figure S4A), indicating that restoration of 3-HK
within the physiological range is sufficient to eliminate
cinnabar-dependent protection. In flies fed 3-HK, the 3-HK/
KYNA ratio also showed a significant, dose-dependent shift
away from protective metabolite levels (Figure 3C). 3-HK
feeding significantly potentiated the toxicity observed in
Htt93Q flies (Figure 3B; p < 0.001 for 1.4mg/ml treatment), indi-
cating that maximal levels of KP-dependent toxicity are not
achieved in this model. Whereas 3-HK treatment of wild-type
larvae resulted in a several-fold increase of 3-HK in the head
of newly eclosed flies, we did not observe any rhabdomere
neurodegeneration (Figures S4A and S4B).
We subsequently interrogated KYNA in similar feeding
experiments with Htt93Q flies, testing four doses over a wide
range of concentrations (0.1 mg/ml to 5 mg/ml). We foundthat the two highest doses (1 mg/ml
and 5 mg/ml) conferred a significant
but modest increase in rhabdomere
number of Htt93Q flies (Figure 3D), and
examination of metabolites revealed
a correlated decrease in flux through
the central KP in these flies (Figure 3E).
Supporting our observations, a recent
study with a synthetic compound simi-
lar in structure to KYNA has shown
some protective effects in HD model
mice [23].
Genetic Manipulation of the KP
Modulates Neurodegeneration
We also tested an additional KP muta-
tion in the cardinal gene (cd1) known to
increase levels of 3-HK [24] (Figure 1A).First, we found a 1.8-fold increase in 3-HK levels in cd1 versus
control flies (Figure 4A), validating the previous study. We
therefore hypothesized that cd1/cd1 flies expressing Htt93Q
would show increased levels of neurodegeneration in the
eye. Surprisingly, we found that the cd1 mutation was neuro-
protective (Figure 4B). When 3-HK and KYNA were examined
in Htt93Q cd1/cd1 flies, we observed no change in 3-HK levels
and anw3-fold increase in KYNA levels compared to controls,
leading to a significant reduction in the 3-HK/KYNA ratio
(Figures 4A, 4C, and 4D). Although the mechanism underlying
this surge in KYNA levels remains to be clarified, our observa-
tion provides further strong and unanticipated support for the
central role of 3-HK and KYNA dynamics in mutant htt toxicity.
Supporting our 3-HK feeding observations, cd1/cd1 control
flies do not exhibit rhabdomere neurodegeneration (Fig-
ure S4D), indicating that flies expressing Htt93Q are specifi-
cally sensitive to perturbations in 3-HK. This was confirmed
with an analysis of Htt20Q flies, which exhibit increased KP
Figure 4. Htt93Q Flies Carrying the cd1 Mutation
Exhibit Reduced Neurodegeneration
(A) Day 1 cd1/cd1 flies in the control elav-GAL4
background exhibit a significant increase in
3-HK, whereas 3-HK levels in Htt93Q cd1/cd1 flies
are unchanged (n = 4–5).
(B) Rhabdomeres in Htt93Q cd1/+ andHtt93Q cd1
/cd1 flies are significantly increased versus
Htt93Q flies at day 1 and day 7 after eclosion
(n = 12–13). In cd control flies, seven rhabdo-
meres are visible per ommatidium (see Fig-
ure S4D).
(C) Day 1 Htt93Q cd1/cd1 flies exhibit anw3-fold
increase in KYNA levels versus Htt93Q flies,
whereas KYNA levels in the elav-GAL4 back-
ground are unchanged (n = 4–5 samples per
genotype).
(D) cd1/cd1 flies in the control elav-GAL4 back-
ground exhibit a significant increase in 3-HK/
KYNA ratios, whereas 3-HK/KYNA ratios in
Htt93Q cd1/cd1 flies are significantly reduced
compared to Htt93Q flies (n = 4–5). ANOVA with
Newman-Keuls post hoc tests, except for (C),
Student’s t test (*p < 0.05; **p < 0.01; ***p < 0.001).
Data are shown as means 6 standard errors of
the mean (SEMs).
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S4D).
Discussion
We have observed that both genetic and chemical inhibition of
KMO ameliorate neurodegeneration in HD model flies, sup-
porting our previous observations that inhibition of KMO is
protective in a yeast model of mutant htt toxicity [25, 26]. We
also found that this neuroprotection is correlated with
decreases in 3-HK relative to KYNA. Importantly, this protec-
tion can be abrogated by 3-HK feeding, showing the causative
nature of this metabolite. Furthermore, a KYNA feeding regime
that forces a neuroprotective ratio of these metabolites also
reduces neurodegeneration in HD flies. Therefore, for the first
time, we show that KPmetabolites directly modulate neurode-
generation in an animal model of neurodegenerative disease.
Finally, our genetic dissection of the KP with vermillion and
cardinal mutants further underscores the critical relationship
between imbalances in the KP and neurodegeneration.
3-HK generates free radicals by auto-oxidation [3, 4], and
this mechanism is believed to underlie 3-HK-dependent
toxicity observed in neuronal cell lines and in primary neurons
[1]. It is therefore likely that 3-HK is contributing to neurode-
generation in our studies by generation of free radicals. At
endogenous concentrations in the mammalian brain, KYNA
functions as a competitive inhibitor of the glycine coagonist
site of the NMDA receptor and a potent, noncompetitive inhib-
itor of the a7 nicotinic acetylcholine receptor [27]. KYNA treat-
ment results in dose-dependent behavioral changes in
rodents, mimicking properties of NMDA receptor antagonists
[7]. Moreover, KYNA is neuroprotective against excitotoxic
lesions and inhibits the release of glutamate at concentrations
in the physiological range [8, 9]. In a study parallel to ours, Mu-
chowski and colleagues found, by using a novel KMO inhibitor,that glutamate reduction by KYNA is the
likely mechanism for neuroprotection in
the central nervous system (CNS) of HDmice [20]. Because flies express orthologs of both NMDA and
a7 nicotinic acetylcholine receptors [28, 29], KYNA could be
conferring neuroprotection by antagonizing these receptors
and decreasing glutamate-dependent excitotoxicity, as well
as by scavenging free radicals [10].
Interestingly, we find that increased 3-HK relative to KYNA is
only neurotoxic in the presence of Htt93Q, suggesting that
general cellular dysfunction due to mutant htt expression
[30] confers a sensitized background for KP modulation. In
a related fashion, we find that expression of Htt20Q is suffi-
cient to induce increased 3-HK/KYNA ratios but does not
confer neurodegeneration—providing further support that
additional Htt93Q-dependent cellular defects are required to
uncover KP-dependent toxicity. A similar observation was
made by Romero and colleagues with flies expressing full-
length htt constructs [31]. These authors found that whereas
expression of either an expanded construct (128QhttFL) or
a nonexpanded construct (16QhttFL) led to elevated resting
synaptic Ca2+ levels, this perturbation was associated with
pathogenesis only in the case of 128QhttFL flies.
Our discovery that inhibition of TDO is protective in the fly
validates this protein as a novel therapeutic target for HD.
TDO and IDO, which are both expressed in the brain [1],
have distinct structural and biochemical characteristics [32],
and selective inhibitors are being actively explored as poten-
tial therapeutic compounds [12]. It is now imperative that
such compounds be tested in animal models of HD, and
perhaps other neurodegenerative disorders, to characterize
their efficacy and therapeutic potential.
In summary, our results are consistent with the view that
modulation of the KP is central to mutant htt toxicity [1]. Our
observations provide genetic and pharmacological support
for the ‘‘kynurenine hypothesis,’’ underscoring the important
role that Drosophila plays in the understanding and pos-
sible development of therapy for human neurodegenerative
Current Biology Vol 21 No 11
966disorders. Our study favors a model in which increased flux
toward KYNA synthesis is neuroprotective in HD, provides
unequivocal evidence that 3-HK, independent of QUIN, is
pathogenic, and shows that reduction of 3-HK relative to
KYNA is therapeutic. Based upon these observations and
a new study from our group in which KMO inhibition is also
beneficial to HD model mice [20], it seems timely to consider
testing the efficacy of KMO inhibitors, and potentially inhibi-
tors of other KP enzymes, in HD patients.
Supplemental Information
Supplemental Information includes four figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.cub.2011.04.028.
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